Source: Manitoba Co-operator
  • Delta 9 Cannabis (DN) gets approval from Health Canada for two expansion approvals
  • The expanded licensed perimeter will allow the company to improve control systems, and improve its operational flow
  • The new purpose-built storage and distribution area will allow Delta 9 to improve its product packaging, case-packing, and distribution efficiency
  • It anticipates that the new storage area will improve its competitive position in provincial markets
  • Delta 9 Cannabis Inc. (DN) is trading at C$0.42 at 1:45 pm PT

Delta 9 Cannabis (DN) has received approval from Health Canada for two expansion approvals for its Winnipeg-based facilities.

The expansion approvals allow for an expansion of the company’s licensed perimeter at its Winnipeg-based facilities, expanding the area currently under license from approximately 80,000 square feet to approximately 95,000 square feet, and the licensing of a new 7,500 square foot purpose-built storage and distribution area.

The expanded licensed perimeter will allow the company to improve control systems, improve the operational flow of its operations, and position the company to better plan for future expansions of its licensed cannabis operations areas.

The new purpose-built storage and distribution area will allow the company to improve its product packaging, case-packing, and distribution efficiency to better allow it to cater to its provincial distribution markets across Canada.

It anticipates that the new storage area will improve its competitive position in provincial markets across the country.

Delta 9 is a cannabis company focused on bringing the highest quality cannabis products to market.

Delta 9 Cannabis Inc. (DN) is trading at C$0.42 at 1:45 pm PT.

More From The Market Online

Tilray Brands seeks US$250M for U.S. cannabis expansion

Global cannabis stock Tilray Brands (TSX:TLRY) intends to raise up to US$250 million to fund its U.S. expansion plan.

The Market Online’s Weekly Cannabis Report – May 17, 2024

This international biopharmaceutical company revealed it has completed the retrospective observational real-world evidence study.

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.